Lupin Recalls Lisinopril Tablets Due to CGMP Deviations
Lupin Pharmaceuticals is recalling 20,556 bottles of Lisinopril 30 mg tablets because they were manufactured using active pharmaceutical ingredients whose intermediates failed specifications.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as a situation where use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling 20,556 bottles of Lisinopril Tablets USP, 30 mg. The affected product is packaged in 500-count bottles (NDC 68180-516-02) and 100-count bottles (NDC 68180-516-01). The specific batch numbers involved are H303487, H303488, and H303489, all with an expiration date of 09/16.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the finished products were manufactured using active pharmaceutical ingredients whose intermediates failed specifications. The product was distributed domestically in the United States. No recalled product was distributed to U.S. Government Agency consignees directly by Lupin, and no recalled product was distributed to any foreign consignees by Lupin.
Consumers and healthcare providers should check their inventory for the specific NDCs and batch numbers listed above. If the product is found, it should be returned to the supplier or disposed of according to local regulations. Patients should consult their healthcare provider for alternative medication options if they are currently using the recalled product.
The recalled product
- Product
- LISINOPRIL (LISINOPRIL)
- Brand
- LISINOPRIL
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Prescription Drug
- Hazard
- Affected units
- 20,556
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Batch number: H303487
- H303488
- H303489
- Exp 09/16
UPCs (3)
- 0368180513018
- 0368180512028
- 0368180513032
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 2 recalled by Lupin Pharmaceuticals Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LISINOPRIL
- HighLisinopril 10 mg Tablets Recalled for Metal Fragment Contamination
FDA (Drugs) · 2024-11-27
- HighLisinopril Tablets Recalled for Embedded Metal Contamination
FDA (Drugs) · 2022-09-21
- HighLupin Recalls Lisinopril Tablets Due to Foreign Tablet Presence
FDA (Drugs) · 2020-08-05
- HighLupin Recalls Lisinopril 5 mg Tablets Due to Product Mix-Up
FDA (Drugs) · 2020-06-17
- ModerateLupin Recalls Lisinopril Tablets Due to Foreign Tablet Mix-Up
FDA (Drugs) · 2020-04-08
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateSertraline tablets recalled because bottle seals are not adhering
FDA (Drugs) · 2025-12-17
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- SevereShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19